PhRMA senior director on 340B program: 'Hospitals abuse the program to boost their profits at the expense of patients'

PhRMA director of public affairs on 340B exploitation: ‘Evidence shows that 340B entities markup medicines by as much 1,000% or more’

Iowa board files charges against FarmaKeio, citing FDA and California actions

HealthLeaders editor on 340B: ‘We continue to have serious concerns about persistent and often illegal abuse of 340B’

Potential medication mix-ups between Inflectra and Zymfentra prompt safety warnings